87 results on '"Raymond, Stéphanie"'
Search Results
2. Valuing emotions and reflecting on group work: A ‘metalogic’ approach to teaching research methods in a university course
- Author
-
Olson, Rebecca E., Raymond, Stephanie, and Smith, Alexandra
- Published
- 2024
- Full Text
- View/download PDF
3. DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.
- Author
-
Soulie, Cathia, Balde, Aliou, Fofana, Djeneba, Charpentier, Charlotte, Bonnafous, Pascale, Sourice, Justine, Monte, Anne De, Avettand-Fenoel, Véronique, Guillou-Guillemette, Hélène Le, Bocket, Laurence, Raymond, Stéphanie, Juillet, Stéphanie Marque, Trabaud, Mary-Anne, Montes, Brigitte, Maillard, Anne, Hartard, Cédric, Alessandri-Gradt, Elodie, Brochot, Etienne, Signori-Schmuck, Anne, and Assoumou, Lambert
- Subjects
VIRAL load ,ANTIRETROVIRAL agents ,HIV ,GENOTYPES ,RALTEGRAVIR ,RNA - Abstract
Background Doravirine is the latest NNRTI to be approved for the treatment of HIV-1 and has a different resistance profile from first-generation NNRTIs. Our aim was to investigate the virological efficacy of antiretroviral treatment including doravirine in people living with HIV-1 (PLWHIV), the factors associated with virological failure (VF) and those associated with the emergence of reverse transcriptase (RT) mutations in the case of VF. Methods A retrospective national survey of PLWHIV who were either naive or experienced on antiretroviral treatment including doravirine was conducted. VF was defined as two consecutive plasma viral loads (VLs) of ≥50 copies/mL or one VL of ≥200 copies/mL. Genotypic resistance tests were interpreted using the Stanford (v9.4.1) and ANRS (v33) algorithms. Results Of the 589 PLWHIV treated with a doravirine-containing regimen, 8.5% were naive and 91.5% had prior antiretroviral experience; 56.9% were infected with HIV-1 B subtype. Overall, 88.3% and 85.1% of participants were virologically controlled at Month (M)3 and M6 of doravirine treatment, respectively. In multivariable analysis, CRF02_AG subtype, higher zenith plasma HIV-1 RNA VL, doravirine initiation in the context of failure and baseline V179D mutation presence were associated with VF. Among 88 PLWHIV who experienced virological failure at M6, 15.9% had a median of 2 (IQR 1–3) HIV RT mutations. In multivariable analysis, the only factor associated with the occurrence of mutations was a genotypic sensitivity score that was not fully sensitive. Conclusions This study is one of the largest to characterize the virological efficacy of doravirine-containing regimens in clinical practice and to identify factors associated with VF or emergence of resistance mutations that should be considered in clinical management. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Testing individual and pooled saliva samples for sars-cov-2 nucleic acid: a prospective study
- Author
-
Migueres, Marion, Vellas, Camille, Abravanel, Florence, Da Silva, Isabelle, Dimeglio, Chloé, Ferrer, Venicia, Raymond, Stéphanie, Mansuy, Jean-Michel, and Izopet, Jacques
- Published
- 2021
- Full Text
- View/download PDF
5. HPV genotyping in clinical samples using long‐read single‐molecule real‐time sequencing.
- Author
-
Pasquier, Christophe, Raymond, Stéphanie, Carcenac, Romain, Demmou, Sofia, Ranger, Noémie, Nicot, Florence, and Izopet, Jacques
- Subjects
HUMAN papillomavirus ,EARLY detection of cancer ,SINGLE molecules - Abstract
Human papillomavirus (HPV) genotyping is widely used, particularly in combination with high‐risk (HR) HPV tests for cervical cancer screening. We developed a genotyping method using sequences of approximately 800 bp in the E6/E7 region obtained by PacBio single molecule real‐time sequencing (SMRT) and evaluated its performance against MY09‐11 L1 sequencing and after the APTIMA HPV genotyping assay. The levels of concordance of PacBio E6/E7 SMRT sequencing with MY09‐11 L1 sequencing and APTIMA HPV genotyping were 100% and 90.8%, respectively. The sensitivity of PacBio E6/EA7 SMRT was slightly greater than that of L1 sequencing and, as expected, lower than that of HR‐HPV tests. In the context of cervical cancer screening, PacBio E6/E7 SMRT is then best used after a positive HPV test. PacBio E6/E7 SMRT genotyping is an attractive alternative for HR and LR‐HPV genotyping of clinical samples. PacBio SMRT sequencing provides unbiased genotyping and can detect multiple HPV infections and haplotypes within a genotype. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Performance of the Xpert HBV Viral Load assay versus the Aptima Quant assay for quantifying hepatitis B virus DNA
- Author
-
Abravanel, Florence, Lhomme, Sébastien, Trémeaux, Pauline, Migueres, Marion, Harter, Agnès, Haslé, Catherine, Bruel, Patrick, Alric, Laurent, Métivier, Sophie, Raymond, Stéphanie, and Izopet, Jacques
- Published
- 2020
- Full Text
- View/download PDF
7. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen
- Author
-
French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group, Raymond, Stéphanie, Nicot, Florence, Pallier, Coralie, Bellecave, Pantxika, Maillard, Anne, Trabaud, Mary Anne, Morand-Joubert, Laurence, Rodallec, Audrey, Amiel, Corinne, Mourez, Thomas, Bocket, Laurence, Beby-Defaux, Agnès, Bouvier-Alias, Magali, Lambert-Niclot, Sidonie, Charpentier, Charlotte, Malve, Brice, Mirand, Audrey, Dina, Julia, Le Guillou-Guillemette, Hélène, Marque-Juillet, Stéphanie, Signori-Schmuck, Anne, Barin, Francis, Si-Mohamed, Ali, Fenoel, Véronique Avettand, Roussel, Catherine, Calvez, Vincent, Saune, Karine, Marcelin, Anne Geneviève, Rodriguez, Christophe, Descamps, Diane, and Izopet, Jacques
- Published
- 2018
8. Neural foundations of creativity: A systematic review
- Author
-
Mullen Raymond, Stephanie
- Published
- 2017
- Full Text
- View/download PDF
9. Comparison of Cobas® HPV and Anyplex™ II HPV28 assays for detecting and genotyping human papillomavirus
- Author
-
Pasquier, Christophe, Sauné, Karine, Raymond, Stéphanie, Boisneau, Jérôme, Courtade, Monique, and Izopet, Jacques
- Published
- 2017
- Full Text
- View/download PDF
10. Human papillomavirus testing using HPV APTIMA® assay and an external cellularity control in self‐collected samples.
- Author
-
Pasquier, Christophe, Raymond, Stéphanie, Duchanois, Delphine, Sauné, Karine, Oliveira‐Mendes, Kevin, Vayssiere, Christophe, and Izopet, Jacques
- Subjects
HUMAN papillomavirus ,EARLY detection of cancer ,CERVICAL cancer ,MESSENGER RNA ,RNA - Abstract
In cervical cancer screening programs, the detection of high‐risk human papillomavirus (HR‐HPV) is now widely implemented on physician‐collected samples and has expanded to include self‐collected samples. The use of a cellularity control (CC) is needed to reduce false‐negative HPV results. An external mRNA CC for the HPV APTIMA® assay was assessed for its analytical performance and the results were compared with both cervix cytobrush samples taken by physicians and self‐collected vaginal samples from 148 women. The performance of the CC was adjusted to control for the presence of cellular mRNA in the ThinPrep® and Multitest® transport media. This CC is user‐friendly but implies to perform two independent assays on PANTHER® automate. Self‐collected vaginal sampling gives a lower median CC results (13.2 vs. 16.9 min) but a higher risk of negative CC results (3.3 vs. 0%). The usefulness of the CC for the HR‐HPV assay may be optimized by the definition of a threshold for a minimum cell number to be tested to increase confidence in HPV‐negative results. The systematic use of an RNA CC increases confidence for HPV RNA assays on self‐collected vaginal samples. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy
- Author
-
Guerveno, Claire, Raymond, Stéphanie, Metsu, David, Gandia, Peggy, Izopet, Jacques, Martin-Blondel, Guillaume, and Delobel, Pierre
- Published
- 2019
- Full Text
- View/download PDF
12. HIV-1 resistance genotyping by ultra-deep sequencing and 6-month virological response to first-line treatment.
- Author
-
Raymond, Stéphanie, Jeanne, Nicolas, Nicot, Florence, Dimeglio, Chloé, Carcenac, Romain, Harter, Agnès, Ranger, Noémie, Martin-Blondel, Guillaume, Delobel, Pierre, and Izopet, Jacques
- Subjects
- *
RALTEGRAVIR , *REVERSE transcriptase inhibitors , *ANTI-HIV agents , *ANTIRETROVIRAL agents , *INTEGRASE inhibitors , *DRUG resistance , *HIV , *HEPATITIS C virus - Abstract
Objectives: To evaluate the routine use of the Sentosa ultra-deep sequencing (UDS) system for HIV-1 polymerase resistance genotyping in treatment-naïve individuals and to analyse the virological response (VR) to first-line antiretroviral treatment.Methods: HIV drug resistance was determined on 237 consecutive samples from treatment-naïve individuals using the Sentosa UDS platform with two mutation detection thresholds (3% and 20%). VR was defined as a plasma HIV-1 virus load <50 copies/mL after 6 months of treatment.Results: Resistance to at least one antiretroviral drug with a mutation threshold of 3% was identified in 29% and 16% of samples according to ANRS and Stanford algorithms, respectively. The ANRS algorithm also revealed reduced susceptibility to at least one protease inhibitor (PI) in 14.3% of samples, to one reverse transcriptase inhibitor in 12.7%, and to one integrase inhibitor (INSTI) in 5.1%. For a mutation threshold of 20%, resistance was identified in 24% and 13% of samples according to ANRS and Stanford algorithms, respectively. The 6 months VR was 87% and was similar in the 58% of patients given INSTI-based treatment, in the 16% given PI-based treatment and in the 9% given NNRTI-based treatment. Multivariate analysis indicated that the VR was correlated with the baseline HIV virus load and resistance to at least one PI at both 3% and 20% mutation detection thresholds (ANRS algorithm).Conclusions: The Vela UDS platform is appropriate for determining antiretroviral resistance in patients on a first-line antiretroviral treatment. Further studies are needed on the use of UDS for therapeutic management. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
13. Whole‐genome single molecule real‐time sequencing of SARS‐CoV‐2 Omicron.
- Author
-
Nicot, Florence, Trémeaux, Pauline, Latour, Justine, Carcenac, Romain, Demmou, Sofia, Jeanne, Nicolas, Ranger, Noémie, De Smet, Clémentine, Raymond, Stéphanie, Dimeglio, Chloé, and Izopet, Jacques
- Subjects
SARS-CoV-2 ,SARS-CoV-2 Omicron variant ,SARS-CoV-2 Delta variant ,SINGLE molecules ,WHOLE genome sequencing - Abstract
New variants and genetic mutations of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) genome can only be identified using accurate sequencing methods. Single molecule real‐time (SMRT) sequencing has been used to characterize Alpha and Delta variants, but not Omicron variants harboring numerous mutations in the SARS‐CoV‐2 genome. This study assesses the performance of a target capture SMRT sequencing protocol for whole genome sequencing (WGS) of SARS‐CoV‐2 Omicron variants and compared it to that of an amplicon SMRT sequencing protocol optimized for Omicron variants. The failure rate of the target capture protocol (6%) was lower than that of the amplicon protocol (34%, p < 0.001) on our data set, and the median genome coverage with the target capture protocol (98.6% [interquartile range (IQR): 86–99.4]) was greater than that with the amplicon protocol (76.6% [IQR: 66–89.6], [p < 0.001]). The percentages of samples with >95% whole genome coverage were 64% with the target capture protocol and 19% with the amplicon protocol (p < 0.05). The clades of 96 samples determined with both protocols were 93% concordant and the lineages of 59 samples were 100% concordant. Thus, target capture SMRT sequencing appears to be an efficient method for WGS, genotyping and detecting mutations of SARS‐CoV‐2 Omicron variants. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Influence of Nasopharyngeal Viral Load on the Spread of the Omicron BA.2 Variant.
- Author
-
Migueres, Marion, Dimeglio, Chloé, Mansuy, Jean-Michel, Abravanel, Florence, Raymond, Stéphanie, Latour, Justine, Jeanne, Nicolas, Ranger, Noémie, Lhomme, Sébastien, Saune, Karine, Tremeaux, Pauline, and Izopet, Jacques
- Subjects
NASOPHARYNX microbiology ,COVID-19 ,VIRAL load ,DESCRIPTIVE statistics ,POLYMERASE chain reaction ,FRIEDMAN test (Statistics) - Abstract
We used variant typing polymerase chain reaction to describe the evolution of severe acute respiratory syndrome coronavirus 2 Omicron sublineages between December 2021 and mid-March 2022. The selective advantage of the BA.2 variant over BA.1 is not due to greater nasopharyngeal viral loads. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Whole‐genome sequencing of SARS‐CoV‐2: Comparison of target capture and amplicon single molecule real‐time sequencing protocols.
- Author
-
Nicot, Florence, Trémeaux, Pauline, Latour, Justine, Jeanne, Nicolas, Ranger, Noémie, Raymond, Stéphanie, Dimeglio, Chloé, Salin, Gérald, Donnadieu, Cécile, and Izopet, Jacques
- Subjects
SARS-CoV-2 ,NUCLEOTIDE sequencing ,SINGLE molecules - Abstract
Fast, accurate sequencing methods are needed to identify new variants and genetic mutations of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) genome. Single‐molecule real‐time (SMRT) Pacific Biosciences (PacBio) provides long, highly accurate sequences by circular consensus reads. This study compares the performance of a target capture SMRT PacBio protocol for whole‐genome sequencing (WGS) of SARS‐CoV‐2 to that of an amplicon PacBio SMRT sequencing protocol. The median genome coverage was higher (p < 0.05) with the target capture protocol (99.3% [interquartile range, IQR: 96.3–99.5]) than with the amplicon protocol (99.3% [IQR: 69.9–99.3]). The clades of 65 samples determined with both protocols were 100% concordant. After adjusting for Ct values, S gene coverage was higher with the target capture protocol than with the amplicon protocol. After stratification on Ct values, higher S gene coverage with the target capture protocol was observed only for samples with Ct > 17 (p < 0.01). PacBio SMRT sequencing protocols appear to be suitable for WGS, genotyping, and detecting mutations of SARS‐CoV‐2. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Virological failure of patients on maraviroc-based antiretroviral therapy
- Author
-
Raymond, Stéphanie, Maillard, Anne, Amiel, Corinne, Peytavin, Gilles, Trabaud, Mary Anne, Desbois, Delphine, Bellecave, Pantxika, Delaugerre, Constance, Soulie, Cathia, Marcelin, Anne Geneviève, Descamps, Diane, Izopet, Jacques, Reigadas, S., Bellecave, P., Pinson-Recordon, P., Fleury, H., Masquelier, B., Signori-Schmuck, A., Morand, P., Bocket, L., Mouna, L., André, P., Tardy, J. C., Trabaud, M. A., Descamps, D., Charpentier, C., Peytavin, G., Brun-Vézinet, F., Haim-Boukobza, S., Roques, A. M., Soulié, C., Lambert-Niclot, S., Malet, I., Wirden, M., Fourati, S., Marcelin, A. G., Calvez, V., Flandre, P., Assoumou, L., Costagliola, D., Morand-Joubert, L., Delaugerre, C., Schneider, V., Amiel, C., Giraudeau, G., Maillard, A., Nicot, F., and Izopet, J.
- Published
- 2015
- Full Text
- View/download PDF
17. Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapy
- Author
-
Raymond, Stéphanie, Saliou, Adrien, Delobel, Pierre, Cazabat, Michelle, Pasquier, Christophe, Jeanne, Nicolas, Sauné, Karine, Massip, Patrice, Marchou, Bruno, and Izopet, Jacques
- Published
- 2014
- Full Text
- View/download PDF
18. Characterization of CXCR4-using HIV-1 during primary infection by ultra-deep pyrosequencing
- Author
-
Raymond, Stéphanie, Saliou, Adrien, Nicot, Florence, Delobel, Pierre, Dubois, Martine, Carcenac, Romain, Sauné, Karine, Marchou, Bruno, Massip, Patrice, and Izopet, Jacques
- Published
- 2013
- Full Text
- View/download PDF
19. Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence
- Author
-
Delobel, Pierre, Cazabat, Michelle, Saliou, Adrien, Loiseau, Claire, Coassin, Lucile, Raymond, Stéphanie, Requena, Mary, Marchou, Bruno, Massip, Patrice, and Izopet, Jacques
- Published
- 2013
- Full Text
- View/download PDF
20. Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism
- Author
-
Raymond, Stéphanie, Recordon-Pinson, Patricia, Saliou, Adrien, Delobel, Pierre, Nicot, Florence, Descamps, Diane, Marcelin, Anne-Geneviève, Flandre, Philippe, Calvez, Vincent, Masquelier, Bernard, Izopet, Jacques, Recordon-Pinson, P., Fleury, H., Masquelier, B., Vabret, A., Pallier, C., Lazrek, M, André, P., Tardy, J. C., Trabaud, M. A., Tamalet, C., Montes, B., Segondy, M., Ferré, V., Cottalorda, J., Macé, M., Descamps, D., Brun-Vézinet, F., Si-Mohammed, A., Charpentier, C., Desbois, D., Dussaix, E., Marcelin, A. G., Soulié, C., Calvez, V., Flandre, F., Morand-Joubert, L., Amiel, C., Schneider, V., Maillard, A., Ruffault, A., Izopet, J., Nicot, F., Delobel, P., and Raymond, S.
- Published
- 2011
- Full Text
- View/download PDF
21. Influence of immune escape and nasopharyngeal virus load on the spread of SARS-CoV-2 Omicron variant.
- Author
-
Migueres, Marion, Dimeglio, Chloé, Trémeaux, Pauline, Abravanel, Florence, Raymond, Stéphanie, Lhomme, Sébastien, Mansuy, Jean-Michel, and Izopet, Jacques
- Published
- 2022
- Full Text
- View/download PDF
22. Genotypic prediction of HIV-1 subtype D tropism
- Author
-
Chaix Marie-Laure, Delobel Pierre, Raymond Stéphanie, Cazabat Michelle, Encinas Stéphanie, Bruel Patrick, Sandres-Sauné Karine, Marchou Bruno, Massip Patrice, and Izopet Jacques
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Background HIV-1 subtype D infections have been associated with rapid disease progression and phenotypic assays have shown that CXCR4-using viruses are very prevalent. Recent studies indicate that the genotypic algorithms used routinely to assess HIV-1 tropism may lack accuracy for non-B subtypes. Little is known about the genotypic determinants of HIV-1 subtype D tropism. Results We determined the HIV-1 coreceptor usage for 32 patients infected with subtype D by both a recombinant virus phenotypic entry assay and V3-loop sequencing to determine the correlation between them. The sensitivity of the Geno2pheno10 genotypic algorithm was 75% and that of the combined 11/25 and net charge rule was 100% for predicting subtype D CXCR4 usage, but their specificities were poor (54% and 68%). We have identified subtype D determinants in the V3 region associated with CXCR4 use and built a new simple genotypic rule for optimizing the genotypic prediction of HIV-1 subtype D tropism. We validated this algorithm using an independent GenBank data set of 67 subtype D V3 sequences of viruses of known phenotype. The subtype D genotypic algorithm was 68% sensitive and 95% specific for predicting X4 viruses in this data set, approaching the performance of genotypic prediction of HIV-1 subtype B tropism. Conclusion The genotypic determinants of HIV-1 subtype D coreceptor usage are slightly different from those for subtype B viruses. Genotypic predictions based on a subtype D-specific algorithm appear to be preferable for characterizing coreceptor usage in epidemiological and pathophysiological studies.
- Published
- 2011
- Full Text
- View/download PDF
23. THETA: a new genotypic approach for predicting HIV-1 CRF02-AG coreceptor usage.
- Author
-
Dimeglio, Chloé, Raymond, Stéphanie, Jeanne, Nicolas, Reynes, Christelle, Carcenac, Romain, Lefebvre, Caroline, Cazabat, Michelle, Nicot, Florence, Delobel, Pierre, and Izopet, Jacques
- Subjects
- *
TROPISMS , *HIV , *VIRUS cloning , *GENETIC techniques - Abstract
Motivation The circulating recombinant form of HIV-1 CRF02-AG is the most frequent non-B subtype in Europe. Anti-HIV therapy and pathophysiological studies on the impact of HIV-1 tropism require genotypic determination of HIV-1 tropism for non-B subtypes. But genotypic approaches based on analysis of the V3 envelope region perform poorly when used to determine the tropism of CRF02-AG. We, therefore, designed an algorithm based on information from the gp120 and gp41 ectodomain that better predicts the tropism of HIV-1 subtype CRF02-AG. Results We used a bio-statistical method to identify the genotypic determinants of CRF02-AG coreceptor use. Toulouse HIV Extended Tropism Algorithm (THETA), based on a Least Absolute Shrinkage and Selection Operator method, uses HIV envelope sequence from phenotypically characterized clones. Prediction of R5X4/X4 viruses was 86% sensitive and that of R5 viruses was 89% specific with our model. The overall accuracy of THETA was 88%, making it sufficiently reliable for predicting the tropism of subtype CRF02-AG sequences. Availability and implementation Binaries are freely available for download at https://github.com/viro-tls/THETA. It was implemented in Matlab and supported on MS Windows platform. The sequence data used in this work are available from GenBank under the accession numbers MK618182-MK618417. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?
- Author
-
Visseaux, Benoit, Assoumou, Lambert, Mahjoub, Nadia, Grude, Maxime, Trabaud, Mary-Anne, Raymond, Stéphanie, Wirden, Marc, Morand-Joubert, Laurence, Roussel, Catherine, Montes, Brigitte, Bocket, Laurence, Fafi-Kremer, Samira, Amiel, Corinne, Monte, Anne De, Stefic, Karl, Pallier, Coralie, Tumiotto, Camille, Maillard, Anne, Vallet, Sophie, and Ferre, Virginie
- Subjects
INFECTION ,HIV ,NON-nucleoside reverse transcriptase inhibitors ,VIRAL load ,NUCLEOSIDE reverse transcriptase inhibitors ,HIV infection epidemiology ,ANTI-HIV agents ,HIV infections ,RESEARCH ,GENETICS ,BIOLOGICAL evolution ,SEQUENCE analysis ,GENETIC mutation ,RESEARCH methodology ,EPIDEMIOLOGY ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,GENOTYPES ,DRUG resistance in microorganisms ,MICROBIAL virulence ,PHARMACODYNAMICS - Abstract
Objectives: Patients with primary HIV-1 infection (PHI) are a particular population, giving important insight about ongoing evolution of transmitted drug resistance-associated mutation (TDRAM) prevalence, HIV diversity and clustering patterns. We describe these evolutions of PHI patients diagnosed in France from 2014 to 2016.Methods: A total of 1121 PHI patients were included. TDRAMs were characterized using the 2009 Stanford list and the French ANRS algorithm. Viral subtypes and recent transmission clusters (RTCs) were also determined.Results: Patients were mainly MSM (70%) living in the Paris area (42%). TDRAMs were identified among 10.8% of patients and rose to 18.6% when including etravirine and rilpivirine TDRAMs. Prevalences of PI-, NRTI-, first-generation NNRTI-, second-generation NNRTI- and integrase inhibitor-associated TDRAMs were 2.9%, 5.0%, 4.0%, 9.4% and 5.4%, respectively. In a multivariable analysis, age >40 years and non-R5 tropic viruses were associated with a >2-fold increased risk of TDRAMs. Regarding HIV diversity, subtype B and CRF02_AG (where CRF stands for circulating recombinant form) were the two main lineages (56% and 20%, respectively). CRF02_AG was associated with higher viral load than subtype B (5.83 versus 5.40 log10 copies/mL, P=0.004). We identified 138 RTCs ranging from 2 to 14 patients and including overall 41% from the global population. Patients in RTCs were younger, more frequently born in France and more frequently MSM.Conclusions: Since 2007, the proportion of TDRAMs has been stable among French PHI patients. Non-B lineages are increasing and may be associated with more virulent CRF02_AG strains. The presence of large RTCs highlights the need for real-time cluster identification to trigger specific prevention action to achieve better control of the epidemic. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
25. Long-term evolution of transmitted CXCR4-using HIV-1 under effective antiretroviral therapy.
- Author
-
Raymond, Stephanie, Jeanne, Nicolas, Nicot, Florence, Lefebvre, Caroline, Carcenac, Romain, Minier, Luce, Chiabrando, Julie, Cazabat, Michelle, Delobel, Pierre, Izopet, Jacques, and Raymond, Stéphanie
- Published
- 2019
- Full Text
- View/download PDF
26. New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017.
- Author
-
Wirden, Marc, De Oliveira, Fabienne, Bouvier-Alias, Magali, Lambert-Niclot, Sidonie, Chaix, Marie-Laure, Raymond, Stéphanie, Si-Mohammed, Ali, Alloui, Chakib, André-Garnier, Elisabeth, Bellecave, Pantxika, Malve, Brice, Mirand, Audrey, Pallier, Coralie, Poveda, Jean-Dominique, Rabenja, Theresa, Schneider, Veronique, Signori-Schmuck, Anne, Stefc, Karl, Calvez, Vincent, and Descamps, Diane
- Published
- 2019
- Full Text
- View/download PDF
27. Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.
- Author
-
Assoumou, Lambert, Bocket, Laurence, Pallier, Coralie, Grude, Maxime, Ait-Namane, Rachid, Izopet, Jacques, Raymond, Stéphanie, Charpentier, Charlotte, Visseaux, Benoit, Wirden, Marc, Trabaud, Mary-Anne, Guillou-Guillemette, Hélène Le, Allaoui, Chakib, Henquell, Cécile, Krivine, Anne, Santos, Georges Dos, Delamare, Catherine, Bouvier-Alias, Magali, Montes, Brigitte, and Ferre, Virginie
- Subjects
DRUG resistance ,ANTIRETROVIRAL agents ,HIV infections ,INTEGRASE inhibitors ,SAFE sex - Abstract
Objectives: We estimated the prevalence of transmitted-drug-resistance-associated mutations (TDRAMs) in antiretroviral-naive chronically HIV-1-infected patients.Patients and Methods: TDRAMs were sought in samples from 660 diagnosed HIV-1-infected individuals in 2015/2016 in 33 HIV clinical centres. Weighted analyses, considering the number of patients followed in each centre, were used to derive representative estimates of the percentage of individuals with TDRAMs. Results were compared with those of the 2010/2011 survey (n = 661) using the same methodology.Results: At inclusion, median CD4 cell counts and plasma HIV-1 RNA were 394 and 350/mm3 (P = 0.056) and 4.6 and 4.6 log10 copies/mL (P = 0.360) in the 2010/2011 survey and the 2015/2016 survey, respectively. The frequency of non-B subtypes increased from 42.9% in 2010/2011 to 54.8% in 2015/2016 (P < 0.001), including 23.4% and 30.6% of CRF02_AG (P = 0.004). The prevalence of virus with protease or reverse-transcriptase TDRAMs was 9.0% (95% CI = 6.8-11.2) in 2010/2011 and 10.8% (95% CI = 8.4-13.2) in 2015/2016 (P = 0.269). No significant increase was observed in integrase inhibitor TDRAMs (6.7% versus 9.2%, P = 0.146). Multivariable analysis showed that men infected with the B subtype were the group with the highest risk of being infected with a resistant virus compared with others (adjusted OR = 2.2, 95% CI = 1.3-3.9).Conclusions: In France in 2015/2016, the overall prevalence of TDRAMs was 10.8% and stable compared with 9.0% in the 2010/2011 survey. Non-B subtypes dramatically increased after 2010. Men infected with B subtype were the group with the highest risk of being infected with a resistant virus, highlighting the need to re-emphasize safe sex messages. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
28. Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.
- Author
-
Marcelin, Anne-Genevieve, Grude, Maxime, Charpentier, Charlotte, Bellecave, Pantxika, Guen, Laura Le, Pallier, Coralie, Raymond, Stéphanie, Mirand, Audrey, Bocket, Laurence, Fofana, Djeneba Bocar, Delaugerre, Constance, Nguyen, Thuy, Montès, Brigitte, Jeulin, Hélène, Mourez, Thomas, Fafi-Kremer, Samira, Amiel, Corinne, Roussel, Catherine, Dina, Julia, and Trabaud, Mary-Anne
- Subjects
INTEGRASE inhibitors ,ANTIRETROVIRAL agents ,GENOTYPES ,INTEGRASES - Abstract
Objectives: To describe integrase strand transfer inhibitor (INSTI) resistance profiles and factors associated with resistance in antiretroviral-naive and -experienced patients failing an INSTI-based regimen in clinical practice.Methods: Data were collected from patients failing an INSTI-containing regimen in a multicentre French study between 2014 and 2017. Failure was defined as two consecutive plasma viral loads (VL) >50 copies/mL. Reverse transcriptase, protease and integrase coding regions were sequenced at baseline and failure. INSTI resistance-associated mutations (RAMs) included in the Agence Nationale de Recherches sur le SIDA genotypic algorithm were investigated.Results: Among the 674 patients, 359 were failing on raltegravir, 154 on elvitegravir and 161 on dolutegravir therapy. Overall, 90% were experienced patients and 389 (58%) patients showed no INSTI RAMs at failure. The strongest factors associated with emergence of at least one INSTI mutation were high VL at failure (OR = 1.2 per 1 log10 copies/mL increase) and low genotypic sensitivity score (GSS) (OR = 0.08 for GSS ≥3 versus GSS = 0-0.5). Patients failing dolutegravir also had significantly fewer INSTI RAMs at failure than patients failing raltegravir (OR = 0.57, P = 0.02) or elvitegravir (OR = 0.45, P = 0.005). Among the 68 patients failing a first-line regimen, 11/41 (27%) patients on raltegravir, 7/18 (39%) on elvitegravir and 0/9 on dolutegravir had viruses with emergent INSTI RAMs at failure.Conclusions: These results confirmed the robustness of dolutegravir regarding resistance selection in integrase in the case of virological failure in routine clinical care. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
29. Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen.
- Author
-
Dimeglio, Chloé, Raymond, Stéphanie, Nicot, Florence, Jeanne, Nicolas, Carcenac, Romain, Lefebvre, Caroline, Izopet, Jacques, and French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group
- Subjects
- *
RILPIVIRINE , *VIROLOGY , *REVERSE transcriptase , *DRUG resistance , *GENOTYPES - Abstract
Objectives: To determine how the load of rilpivirine-resistant variants (mutational load) influences the virological response (VR) of HIV-1-infected patients to a rilpivirine-based first-line regimen.Patients and Methods: Four hundred and eighty-nine patients infected with HIV-1 whose reverse transcriptase gene had been successfully resistance genotyped using next-generation sequencing were given a first-line regimen containing rilpivirine. Variables associated with the VR at 12 months were identified using a logistic model. The results were used to build a multivariate model for each mutational load threshold and the R2 variations were analysed to identify the mutational load threshold that best predicted the VR.Results: The mutational load at baseline was the only variable linked to the VR at 12 months (P < 0.01). The VR at 12 months decreased from 96.9% to 83.4% when the mutational load was >1700 copies/mL and to 50% when the mutational load was > 9000 copies/mL. The threshold of 9000 copies/mL was associated with the VR at 12 months with an OR of 36.7 (95% CI 4.7-285.1). The threshold of 1700 copies/mL was associated with the VR at 12 months with an OR of 7.2 (95% CI 1.4-36.8).Conclusions: There is quantifiable evidence that determining a mutational load threshold can be used to identify those patients on a first-line regimen containing rilpivirine who are at risk of virological failure. The clinical management of HIV-infected patients can be improved by evaluating the frequency of mutant variants at a threshold of < 20% together with the plasma HIV-1 viral load at the time of resistance genotyping. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
30. CCR5 structural plasticity shapes HIV-1 phenotypic properties.
- Author
-
Zhou, Zhicheng, Staropoli, Isabelle, Benureau, Yann, Jin, Jun, Arenzana-Seisdedos, Fernando, Brelot, Anne, Colin, Philippe, Lagane, Bernard, Garcia-Perez, Javier, Gonzalez, Nuria, Alcami, Jose, Gasser, Romain, Armani-Tourret, Marie, Raymond, Stéphanie, Izopet, Jacques, Delobel, Pierre, Connell, Bridgette J., and Lortat-Jacob, Hugues
- Subjects
CHEMOKINE receptors ,IMMUNE response ,HIV infections ,MONOCLONAL antibodies ,GLYCOPROTEINS - Abstract
CCR5 plays immune functions and is the coreceptor for R5 HIV-1 strains. It exists in diverse conformations and oligomerization states. We interrogated the significance of the CCR5 structural diversity on HIV-1 infection. We show that envelope glycoproteins (gp120s) from different HIV-1 strains exhibit divergent binding levels to CCR5 on cell lines and primary cells, but not to CD4 or the CD4i monoclonal antibody E51. This owed to differential binding of the gp120s to different CCR5 populations, which exist in varying quantities at the cell surface and are differentially expressed between different cell types. Some, but not all, of these populations are antigenically distinct conformations of the coreceptor. The different binding levels of gp120s also correspond to differences in their capacity to bind CCR5 dimers/oligomers. Mutating the CCR5 dimerization interface changed conformation of the CCR5 homodimers and modulated differentially the binding of distinct gp120s. Env-pseudotyped viruses also use particular CCR5 conformations for entry, which may differ between different viruses and represent a subset of those binding gp120s. In particular, even if gp120s can bind both CCR5 monomers and oligomers, impairment of CCR5 oligomerization improved viral entry, suggesting that HIV-1 prefers monomers for entry. From a functional standpoint, we illustrate that the nature of the CCR5 molecules to which gp120/HIV-1 binds shapes sensitivity to inhibition by CCR5 ligands and cellular tropism. Differences exist in the CCR5 populations between T-cells and macrophages, and this is associated with differential capacity to bind gp120s and to support viral entry. In macrophages, CCR5 structural plasticity is critical for entry of blood-derived R5 isolates, which, in contrast to prototypical M-tropic strains from brain tissues, cannot benefit from enhanced affinity for CD4. Collectively, our results support a role for CCR5 heterogeneity in diversifying the phenotypic properties of HIV-1 isolates and provide new clues for development of CCR5-targeting drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
31. Maraviroc exposure is influenced by exogenous thyrotoxicosis.
- Author
-
Metsu, David, Aquilina, Christian, Delobel, Pierre, Gandia, Peggy, Savagner, Frédérique, Raymond, Stéphanie, Caron, Philippe, and Martin-Blondel, Guillaume
- Published
- 2021
- Full Text
- View/download PDF
32. Performance comparison of deep sequencing platforms for detecting HIV-1 variants in the pol gene.
- Author
-
Nicot, Florence, Jeanne, Nicolas, Raymond, Stéphanie, Delfour, Olivier, Carcenac, Romain, Lefebvre, Caroline, Sauné, Karine, Delobel, Pierre, and Izopet, Jacques
- Abstract
The present study compares the performances of an in-house sequencing protocol developed on MiSeq, the Sanger method, and the 454 GS-FLX for detecting and quantifying drug-resistant mutations (DRMs) in the human immunodeficiency virus polymerase gene (reverse transcriptase [RT] and protease [PR]). MiSeq sequencing identified all the resistance mutations detected by bulk sequencing (n = 84). Both the MiSeq and 454 GS-FLX platforms identified 67 DRMs in the RT and PR regions, but a further 25 DRMs were identified by only one or other of them. Pearson's analysis showed good concordance between the percentage of drug-resistant variants determined by MiSeq and 454 GS-FLX sequencing (p = .77, P < .0001). The MiSeq platform is as accurate as the 454 GS-FLX Roche system for determining RT and PR DRMs and could be used for monitoring human immunodeficiency virus type 1 drug resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
33. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine- Based First-line Regimen.
- Author
-
Raymond, Stéphanie, Nicot, Florence, Pallier, Coralie, Bellecave, Pantxika, Maillard, Anne, Trabaud, Mary Anne, Morand-Joubert, Laurence, Rodallec, Audrey, Amiel, Corinne, and Mourez, Thomas
- Subjects
- *
HIV infections , *VIRAL load , *ANTIRETROVIRAL agents , *TREATMENT effectiveness , *REVERSE transcriptase inhibitors , *CD4 lymphocyte count , *RILPIVIRINE , *PHARMACODYNAMICS - Abstract
Background. Minority resistant variants of human immunodeficiency virus type 1 (HIV-1) could influence the virological response to treatment based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). Data on minority rilpivirine-resistant variants are scarce. This study used next-generation sequencing (NGS) to identify patients harboring minority resistant variants to nucleos(t)ide reverse transcriptase inhibitors and NNRTIs and to assess their influence on the virological response (VR). Methods. All the subjects, 541 HIV-1--infected patients started a first-line regimen containing rilpivirine. VR was defined as a HIV-1 RNA load <50 copies/mL at month 6 with continued suppression at month 12. NGS was performed at baseline (retrospectively) on the 454 GS-FLX platform (Roche). Results. NGS revealed resistance-associated mutations accounting for 1% to <5% of variants in 17.2% of samples, for 5%-20% in 5.7% of samples, and for >20% in 29% of samples. We identified 43 (8.8%) and 36 (7.4%) patients who harbored rilpivirine-resistant variants with a 1% sensitivity threshold according to the French National Agency for Research on AIDS and Viral Hepatitis and Stanford algorithms, respectively. The VR was 96.9% at month 12. Detection of minority rilpivirine resistant variants was not associated with virological failure (VF). Multivariate analysis indicated that VF at month 12 was associated with a CD4 count <250 cells/µL at baseline, a slower decrease in viral load at month 3, and rilpivirine resistance at baseline using the Stanford algorithm with a 20% threshold. Conclusions. Minority resistant variants had no impact on the VR of treatment-naive patients to a rilpivirine-based regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
34. HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform.
- Author
-
Raymond, Stéphanie, Nicot, Florence, Carcenac, Romain, Lefebvre, Caroline, Jeanne, Nicolas, Saune, Karine, Delobel, Pierre, and Izopet, Jacques
- Subjects
- *
THERAPEUTICS , *GENETIC mutation , *NUCLEOTIDE sequence , *HIV infections , *HIV-positive persons , *PROTEINS , *RESEARCH , *SEQUENCE analysis , *RESEARCH methodology , *LABORATORIES , *RNA , *EVALUATION research , *MEDICAL cooperation , *BIOINFORMATICS , *COMPARATIVE studies , *AUTOMATION , *GENES , *GENOTYPES , *GENETIC techniques , *DRUG resistance in microorganisms , *HIV , *MICROBIAL sensitivity tests - Abstract
Objectives: To evaluate the diagnostic performance of the Vela next-generation sequencing (NGS) system in conjunction with the Sentosa SQ HIV Genotyping Assay for genotyping HIV-1.Methods: Plasma RNA was extracted and templates prepared with the Sentosa SX instrument before sequencing the HIV-1 polymerase on the Sentosa SQ301 Sequencer (PGM IonTorrent). The Vela NGS System was compared with direct sequencing and the 454 GS-FLX (Roche) and MiSeq (Illumina) systems for genotypic resistance testing on clinical samples.Results: The Vela NGS system detected majority resistance mutations in subtype B and CRF02-AG samples at 500 copies/mL and minority variants with a sensitivity of 5% at 100 000 copies/mL. The Vela NGS system and direct sequencing identified resistance mutations with 97% concordance in 46 clinical samples. Vela identified 1/20 of the 1%-5% mutations identified by 454, 5/12 of the 5%-20% mutations and 60/61 of the >20% mutations. Vela identified 3/14 of the 1%-5% mutations identified by MiSeq, 0/2 of the 5%-20% mutations and 47/47 of the >20% mutations. The resistance mutation quantifications by Vela and 454 were concordant (bias: 2.31%), as were those by Vela and MiSeq (bias: 1.06%).Conclusions: The Vela NGS system provides automated nucleic acid extraction, PCR reagent distribution, library preparation and bioinformatics analysis. The analytical performance was very good when compared with direct sequencing, but was less sensitive than two other NGS platforms for detecting minority variants. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
35. Patterns of residual HIV-1 RNA shedding in the seminal plasma of patients on effective antiretroviral therapy.
- Author
-
Pasquier, Christophe, Walschaerts, Marie, Raymond, Stéphanie, Moinard, Nathalie, Saune, Karine, Daudin, Myriam, Izopet, Jacques, and Bujan, Louis
- Published
- 2017
- Full Text
- View/download PDF
36. Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.
- Author
-
Soulie, Cathia, Grudé, Maxime, Descamps, Diane, Amiel, Corinne, Morand-Joubert, Laurence, Raymond, Stéphanie, Pallier, Coralie, Bellecave, Pantxika, Reigadas, Sandrine, Trabaud, Mary-Anne, Delaugerre, Constance, Montes, Brigitte, Barin, Francis, Ferré, Virginie, Jeulin, Hélène, Alloui, Chakib, Yerly, Sabine, Signori-Schmuck, Anne, Guigon, Aurélie, and Fafi-Kremer, Samira
- Subjects
HIV infections ,THERAPEUTICS ,VIRAL load ,VIRAL encephalitis ,MILD cognitive impairment ,NEUROLOGICAL disorders - Abstract
Background: HIV therapy reduces the CSF HIV RNA viral load (VL) and prevents disorders related to HIV encephalitis. However, these brain disorders may persist in some cases. A large population of antiretroviral-treated patients who had a VL > 1.7 log 10 copies/mL in CSF with detectable or undetectable VL in plasma associated with cognitive impairment was studied, in order to characterize discriminatory factors of these two patient populations.Methods: Blood and CSF samples were collected at the time of neurological disorders for 227 patients in 22 centres in France and 1 centre in Switzerland. Genotypic HIV resistance tests were performed on CSF. The genotypic susceptibility score was calculated according to the last Agence Nationale de Recherche sur le Sida et les hépatites virales Action Coordonnée 11 (ANRS AC11) genotype interpretation algorithm.Results: Among the 227 studied patients with VL > 1.7 log 10 copies/mL in CSF, 195 had VL detectable in plasma [median (IQR) HIV RNA was 3.7 (2.7-4.7) log 10 copies/mL] and 32 had discordant VL in plasma (VL < 1.7 log 10 copies/mL). The CSF VL was lower (median 2.8 versus 4.0 log 10 copies/mL; P < 0.001) and the CD4 cell count was higher (median 476 versus 214 cells/mm 3 ; P < 0.001) in the group of patients with VL < 1.7 log 10 copies/mL in plasma compared with patients with plasma VL > 1.7 log 10 copies/mL. Resistance to antiretrovirals was observed in CSF for the two groups of patients.Conclusions: Fourteen percent of this population of patients with cognitive impairment and detectable VL in CSF had well controlled VL in plasma. Thus, it is important to explore CSF HIV (VL and genotype) even if the HIV VL is controlled in plasma because HIV resistance may be observed. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
37. Accurate quantification of CXCR4-using HIV-1 variants by Illumina deep-sequencing.
- Author
-
Raymond, Stéphanie, Delaugerre, Constance, Nicot, Florence, Assoumou, Lambert, Lancar, Rémi, Beniguel, Lydie, Izopet, Jacques, and ANRS 146 OPTIMAL study group
- Published
- 2018
- Full Text
- View/download PDF
38. HIV-1 Tropism During Primary Infections in France: 1996-2014.
- Author
-
Raymond, Stéphanie, Nicot, Florence, Sauné, Karine, Cazabat, Michelle, Pasquier, Christophe, Massip, Patrice, Marchou, Bruno, Delobel, Pierre, and Izopet, Jacques
- Abstract
HIV-1 was mainly CCR5 tropic in recent seroconverters. We analyzed the coreceptor use in 239 primary HIV-1 infections (PHIs) between 1996 and 2014 using a validated recombinant virus phenotypic entry assay. CXCR4-using viruses were detected in 8.3%, 3.8%, and 6.1% of PHIs from 1996 to 2004, 2005 to 2009, and 2010 to 2014, respectively. The presence of CXCR4-using viruses was associated with the virological failure of antiretroviral treatment initiated during PHI (odds ratio, 7.9; 95% confidence interval, 1.1 to 56.5). The phenotypic tropism assay data show that the prevalence of X4 tropic transmitted viruses was stable in this French cohort of PHIs between 1996 and 2014. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
39. No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive maraviroc therapy.
- Author
-
Raymond, Stéphanie, Nicot, Florence, Carcenac, Romain, Jeanne, Nicolas, Cazabat, Michelle, Requena, Mary, Cuzin, Lise, Delobel, Pierre, Izopet, Jacques, and ANRS 145 MARIMUNO Study Group
- Published
- 2016
- Full Text
- View/download PDF
40. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.
- Author
-
Soulie, Cathia, Descamps, Diane, Grudé, Maxime, Schneider, Véronique, Trabaud, Mary-Anne, Morand-Joubert, Laurence, Delaugerre, Constance, Montes, Brigitte, Barin, Francis, Ferre, Virginie, Raymond, Stéphanie, Jeulin, Hélène, Alloui, Chakib, Yerly, Sabine, Pallier, Coralie, Reigadas, Sandrine, Signori-Schmuck, Anne, Guigon, Aurélie, Fafi-Kremer, Samira, and Haïm-Boukobza, Stéphanie
- Published
- 2015
- Full Text
- View/download PDF
41. Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load.
- Author
-
Migueres, Marion, Dimeglio, Chloé, Trémeaux, Pauline, Raymond, Stéphanie, Lhomme, Sébastien, Da Silva, Isabelle, Oliveira Mendes, Kévin, Abravanel, Florence, Félicé, Marie-Pierre, Mansuy, Jean-Michel, and Izopet, Jacques
- Subjects
SARS-CoV-2 Delta variant ,COVID-19 ,VACCINATION status ,MEDICAL screening ,VIRAL transmission ,COVID-19 testing - Abstract
Studies comparing SARS-CoV-2 nasopharyngeal (NP) viral load (VL) according to virus variant and host vaccination status have yielded inconsistent results. We conducted a single center prospective study between July and September 2021 at the drive-through testing center of the Toulouse University Hospital. We compared the NP VL of 3775 patients infected by the Delta (n = 3637) and Alpha (n = 138) variants, respectively. Patient's symptoms and vaccination status (2619 unvaccinated, 636 one dose and 520 two doses) were recorded. SARS-CoV-2 RNA testing and variant screening were assessed by using Thermo Fisher
® TaqPath™ COVID-19 and ID solutions® ID™ SARS-CoV-2/VOC evolution Pentaplex assays. Delta SARS-CoV-2 infections were associated with higher VL than Alpha (coef = 0.68; p ≤ 0.01) independently of patient's vaccination status, symptoms, age and sex. This difference was higher for patients diagnosed late after symptom onset (coef = 0.88; p = 0.01) than for those diagnosed early (coef = 0.43; p = 0.03). Infections in vaccinated patients were associated with lower VL (coef = −0.18; p ≤ 0.01) independently of virus variant, symptom, age and sex. Our results suggest that Delta infections could lead to higher VL and for a longer period compared to Alpha infections. By effectively reducing the NP VL, vaccination could allow for limiting viral spread, even with the Delta variant. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
42. HIV-1 Tropism and Liver Fibrosis in HIV--HCV Co-Infected Patients.
- Author
-
Abravanel, Florence, Raymond, Stéphanie, Pambrun, Elodie, Winnock, Maria, Bonnard, Philippe, Sogni, Philippe, Trimoulet, Pascale, Dabis, François, Salmon-Ceron, Dominique, and Izopet, Jacques
- Subjects
- *
AMPHIPODA , *MARINE resources conservation , *EUKARYOTES , *NIPHARGUS , *ANIMAL species , *BACTERIA - Abstract
Background and Aims: Hepatic stellate cells, the major producers of extracellular matrix in the liver, and hepatocytes bear CXCR4 and CCR5, the two main co-receptors for entry of the human immunodeficiency virus (HIV). In vitro studies suggest that HIV-envelope proteins can modulate the replication of hepatitis C virus (HCV) and fibrogenesis. We investigated the influence of HIV tropism on liver fibrosis and the concentration of HCV RNA in HIV--HCV co-infected patients. Methods: We used a phenotypic assay to assess HIV tropism in 172 HCV--HIV co-infected patients: one group (75 patients) had mild fibrosis (score ≤F2) and the other (97 patients) had severe fibrosis (score >F2). We also assessed the relationship between HIV tropism and HCV RNA concentration in all these patients. We also followed 34 of these patients for 3 years to determine the evolution of HIV tropism and liver fibrosis, estimated by liver stiffness. Results: Initially, most patients (91.8%) received a potent antiretroviral therapy. CXCR4-using viruses were found in 29% of patients. The only factor associated with a CXCR4-using virus infection in multivariate analysis was the nadir of CD4 cells: <200/mm³ (OR: 3.94, 95%CI: 1.39-11.14). The median HCV RNA concentrations in patients infected with R5 viruses, those with dual-mixed viruses and those with X4 viruses, were all similar. The prevalence of CXCR4-using viruses in patients with mild fibrosis (≤F2) (31%) and those with severe fibrosis (F3--F4) (28%, p = 0.6) was similar. Longitudinal analyses showed that the presence of CXCR4-using viruses did not increase the likelihood of fibrosis progression, evaluated by measuring liver stiffness. Conclusions: The presence of CXCR4-using viruses in patients receiving a potent antiretroviral therapy does not influence HCV RNA concentration or liver fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
43. Phenotyping methods for determining HIV tropism and applications in clinical settings.
- Author
-
Raymond, Stéphanie, Delobel, Pierre, and Izopet, Jacques
- Published
- 2012
- Full Text
- View/download PDF
44. X4 Tropic Multi-Drug Resistant Quasi-Species Detected at the Time of Primary HIV-1 Infection Remain Exclusive or at Least Dominant Far from PHI.
- Author
-
Ghosn, Jade, Galimand, Julie, Raymond, Stéphanie, Meyer, Laurence, Deveau, Christiane, Goujard, Cécile, Izopet, Jacques, Rouzioux, Christine, and Chaix, Marie-Laure
- Subjects
MULTIDRUG resistance ,HIV infections ,NUCLEIC acids ,FOLLOW-up studies (Medicine) ,CLONING ,DEOXYRIBOSE ,GENETIC mutation - Abstract
Our objective was to analyze the evolution of resistance mutations (RM) and viral tropism of multi-drug-resistant (MDR) strains detected at primary HIV-1 infection (PHI). MDR HIV strain was defined as the presence of genotypic resistance to at least 1 antiretroviral of the 3 classes. Tropism determinations (CCR5 or CXCR4) were performed on baseline plasma HIV-RNA and/or PBMC-HIV-DNA samples, then during follow-up using population-based sequencing of V3 loop and phenotypic tests. Clonal analysis was performed at baseline for env, RT and protease genes, and for HIV-DNA env gene during follow-up. Five patients were eligible. At baseline, RT, protease and env clones from HIV-RNA and HIV-DNA were highly homogenous for each patient; genotypic tropism was R5 in 3 (A,B,C) and X4 in 2 patients (D,E). MDR strains persisted in HIV-DNA throughout follow-up in all patients. For patient A, tropism remained R5 with concordance between phenotypic and genotypic tests. Clonal analysis on Month (M) 78 HIV-DNA evidenced exclusively R5 (21/21) variants. In patient B, clonal analysis at M36 showed exclusively R5 variants (19/19) using both genotypic and phenotypic tests. In patient C, baseline tropism was R5 by genotypic test and R5/X4 by phenotypic test. An expansion of these X4 clones was evidenced by clonal analysis on M72 HIV-DNA (12/14 X4 and 2/14 R5 variants). In patient D, baseline tropism was X4 with concordance between both techniques and HIV-RNA and HIV-DNA remained X4-tropic up to M72, confirmed by the clonal analysis. Patient E harboured highly homogenous X4-using population at baseline; tropism was unchanged at M1 and M18. In all patients, the initial MDR population was highly homogenous initially, supporting the early expansion of a monoclonal population and its long-term persistence. X4-tropic variants present at baseline were still exclusive (patients D and E) or dominant (at least one time point, patient C) far from PHI. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
45. Genotypic prediction of HIV-1 subtype D tropism.
- Author
-
Raymond, Stéphanie, Delobel, Pierre, Chaix, Marie-Laure, Cazabat, Michelle, Encinas, Stéphanie, Bruel, Patrick, Sandres-Sauné, Karine, Marchou, Bruno, Massip, Patrice, and Izopet, Jacques
- Subjects
- *
HIV , *HIV-positive persons , *HIV infections , *MICROORGANISMS , *RECOMBINANT viruses , *VIRUS diseases - Abstract
Background: HIV-1 subtype D infections have been associated with rapid disease progression and phenotypic assays have shown that CXCR4-using viruses are very prevalent. Recent studies indicate that the genotypic algorithms used routinely to assess HIV-1 tropism may lack accuracy for non-B subtypes. Little is known about the genotypic determinants of HIV-1 subtype D tropism. Results: We determined the HIV-1 coreceptor usage for 32 patients infected with subtype D by both a recombinant virus phenotypic entry assay and V3-loop sequencing to determine the correlation between them. The sensitivity of the Geno2pheno10 genotypic algorithm was 75% and that of the combined 11/25 and net charge rule was 100% for predicting subtype D CXCR4 usage, but their specificities were poor (54% and 68%). We have identified subtype D determinants in the V3 region associated with CXCR4 use and built a new simple genotypic rule for optimizing the genotypic prediction of HIV-1 subtype D tropism. We validated this algorithm using an independent GenBank data set of 67 subtype D V3 sequences of viruses of known phenotype. The subtype D genotypic algorithm was 68% sensitive and 95% specific for predicting X4 viruses in this data set, approaching the performance of genotypic prediction of HIV-1 subtype B tropism. Conclusion: The genotypic determinants of HIV-1 subtype D coreceptor usage are slightly different from those for subtype B viruses. Genotypic predictions based on a subtype D-specific algorithm appear to be preferable for characterizing coreceptor usage in epidemiological and pathophysiological studies. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
46. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage
- Author
-
Raymond, Stéphanie, Delobel, Pierre, Mavigner, Maud, Cazabat, Michelle, Souyris, Corinne, Encinas, Stéphanie, Bruel, Patrick, Sandres-Sauné, Karine, Marchou, Bruno, Massip, Patrice, and Izopet, Jacques
- Subjects
- *
RECOMBINANT viruses , *PHENOTYPES , *CHEMOKINES , *CELL receptors , *HIV , *VIRAL load , *BLOOD plasma , *CLINICAL trials - Abstract
Abstract: Background: Clinical trials of CCR5 antagonists have relied on the phenotypic determination of HIV-1 coreceptor usage. Few phenotypic assays are available, with few data on their concordance, and none has been designed to determine tropism from cell-associated HIV-1 DNA. Objectives: To assess the performance of the new Toulouse Tropism Test (TTT) phenotypic assay to characterize HIV-1 tropism using blood plasma and peripheral blood mononuclear cells (PBMC). Study design: 434 plasma and 168 PBMC samples were tested with the TTT assay. We determined the correlation between our assay results on plasma samples and those of the commercial Trofile™ assay. Results: The TTT assay determined the tropism of 97% of samples after successful amplification of the env gene. It performed well on both cell samples and plasma samples with various HIV-1 loads and subtypes. It detected 0.5% of minor CXCR4-using variants in the virus population. The TTT and the Trofile™ assays were >90% concordant for predicting HIV-1 tropism. Conclusion: We have validated a new recombinant virus phenotypic assay for determining HIV-1 tropism using both plasma and cell samples from patients who are candidates for treatment with CCR5 antagonists. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
47. Prediction of HIV Type 1 Subtype C Tropism by Genotypic Algorithms Built From Subtype B Viruses.
- Author
-
Raymond, Stéphanie, Delobel, Pierre, Mavigner, Maud, Ferradini, Laurent, Cazabat, Michelle, Souyris, Corinne, Sandres-Sauné, Karine, Pasquier, Christophe, Marchou, Bruno, Massip, Patrice, and Izopet, Jacques
- Subjects
- *
HIV , *RECOMBINANT viruses , *VIRAL replication , *HIV-positive persons , *PHENOTYPES - Abstract
The article presents a study which examines the HIV type 1 coreceptor usage by genotypic algorithms that is built from the subtype B virus. The study performed a recombinant virus phenotypic entry assay to 52 patients infected with HIV-1 subtype C virus that were recruited in Malawi and another 21 patients recruited in France. It shows that the patient's virological and clinical characteristics were not significantly different according to CCR5 or CXCR4 virus coreceptor usage.
- Published
- 2010
- Full Text
- View/download PDF
48. Performance evaluation of the Vela Dx Sentosa next-generation sequencing system for HIV-1 DNA genotypic resistance.
- Author
-
Raymond, Stéphanie, Nicot, Florence, Abravanel, Florence, Minier, Luce, Carcenac, Romain, Lefebvre, Caroline, Harter, Agnès, Martin-Blondel, Guillaume, Delobel, Pierre, and Izopet, Jacques
- Subjects
- *
NUCLEOTIDE sequencing , *VIRAL load , *PERFORMANCE evaluation , *INTEGRASE inhibitors , *DRUG resistance , *DNA - Abstract
• HIV-1 DNA resistance genotyping may help guiding treatment simplification. • We compared the Sentosa NGS assay with Sanger sequencing for DNA genotyping. • Automated DNA extraction and NGS accurately predicted HIV DNA drug resistance. • Further investigation should clarify the clinical impact of resistance in DNA. Patients on antiretroviral therapy could benefit from HIV-1 DNA resistance genotyping for exploring virological failure with low viral load or to guide treatment simplification. Few new generation sequencing data are available. To check that the automated deep sequencing Sentosa platform (Vela DX) detected minority resistant variants well enough for HIV DNA genotyping. We evaluated the Sentosa SQ HIV genotyping assay with automated extraction on 40 DNA longitudinal samples from treatment-experienced patients by comparison with Sanger sequencing. HIV drug resistance was interpreted using the ANRS algorithm (v29) at the threshold of 20 % and 3 %. The Sentosa SQ HIV genotyping assay was 100 % successful to amplify and sequence PR and RT and 86 % to amplify and sequence IN when the HIV DNA load was >2.5 log copies/million cells. The Sentosa and Sanger sequencing were concordant for predicting PR-RT resistance at the threshold of 20 % in 14/18 samples successfully sequenced. A higher level of resistance was predicted by Sentosa in three samples and by Sanger in one sample. The prevalence of resistance was 7 % to PI, 59 % to NRTI, 31 % to NNRTI and 20 % to integrase inhibitors using the Sentosa SQ genotyping assay at the threshold of 3 %. Seven additional mutations <20 % were detected using the Sentosa assay. Automated DNA extraction and sequencing using the Sentosa SQ HIV genotyping assay accurately predicted HIV DNA drug resistance by comparison with Sanger. Prospective studies are needed to evaluate the clinical interest of HIV DNA genotyping. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
49. Performance comparison of next-generation sequencing platforms for determining HIV-1 coreceptor use.
- Author
-
Raymond, Stéphanie, Nicot, Florence, Jeanne, Nicolas, Delfour, Olivier, Carcenac, Romain, Lefebvre, Caroline, Cazabat, Michelle, Sauné, Karine, Delobel, Pierre, and Izopet, Jacques
- Abstract
The coreceptor used by HIV-1 must be determined before a CCR5 antagonist, part of the arsenal of antiretroviral drugs, is prescribed because viruses that enter cells using the CXCR4 coreceptor are responsible for treatment failure. HIV-1 tropism is also correlated with disease progression and so must be determined for virological studies. Tropism can be determined by next-generation sequencing (NGS), but not all of these new technologies have been fully validated for use in clinical practice. The Illumina NGS technology is used in many laboratories but its ability to predict HIV-1 tropism has not been evaluated while the 454 GS-Junior (Roche) is used for routine diagnosis. The genotypic prediction of HIV-1 tropism is based on sequencing the V3 region and interpreting the results with an appropriate algorithm. We compared the performances of the MiSeq (Illumina) and 454 GS-Junior (Roche) systems with a reference phenotypic assay. We used clinical samples for the NGS tropism predictions and assessed their ability to quantify CXCR4-using variants. The data show that the Illumina platform can be used to detect minor CXCR4-using variants in clinical practice but technical optimization are needed to improve quantification. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
50. Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism.
- Author
-
Dubois, Martine, Cazabat, Michelle, Nicot, Florence, Raymond, Stéphanie, Izopet, Jacques, Delobel, Pierre, Jeanne, Nicolas, Saliou, Adrien, Carcenac, Romain, Lefebvre, Caroline, and Loiseau, Claire
- Subjects
HIV ,PYROSEQUENCING ,VIRAL tropism ,GENETIC databases ,CXCR4 receptors ,GENETICS - Abstract
HIV-1 coreceptor usage must be accurately determined before starting CCR5 antagonist-based treatment as the presence of undetected minor CXCR4-using variants can cause subsequent virological failure. Ultra-deep pyrosequencing of HIV-1 V3 env allows to detect low levels of CXCR4-using variants that current genotypic approaches miss. However, the computation of the mass of sequence data and the need to identify true minor variants while excluding artifactual sequences generated during amplification and ultra-deep pyrosequencing is rate-limiting. Arbitrary fixed cut-offs below which minor variants are discarded are currently used but the errors generated during ultra-deep pyrosequencing are sequence-dependant rather than random. We have developed an automated processing of HIV-1 V3 env ultra-deep pyrosequencing data that uses biological filters to discard artifactual or non-functional V3 sequences followed by statistical filters to determine position-specific sensitivity thresholds, rather than arbitrary fixed cut-offs. It allows to retain authentic sequences with point mutations at V3 positions of interest and discard artifactual ones with accurate sensitivity thresholds. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.